In 2012, the Agency for Healthcare Research and Quality (AHRQ) set out to develop the Registry of Patient Registries (RoPR) as a one-stop repository of information about patient registries focused on, but not exclusive to, U.S.-based registries.

Boehringer Ingelheim (BI) GmbH's clinical hold on the oral beta secretase (BACE) inhibitor BI 1181181 for Alzheimer's disease (AD) because of skin reactions in some patients put a dent in shares of partner Vitae Pharmaceuticals Inc., but if worse comes to worse, the pair can move on to a different, structurally distinct candidate in the same class that's ready for testing.

Recent outbreaks of respiratory syncytial virus (RSV) in Alabama, Arizona and Colorado children put renewed attention on the disease for which there is no approved therapy in adults, just as Adma Biologics Inc. reported more data from the pivotal phase III trial with RI-002 in primary immune deficiency (PIDD) that included encouraging results in RSV and other pathogens.

"We're unable to draw any conclusions about efficacy [against the specific infectious agents] from these increases in antibody titers, but it's good to note that from the patients the trial was based on, we were able to generate this type of dose response, if you will," Adam Grossman, Adma's CEO, told BioWorld Today. "We think it's encouraging, and we think